Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease (ESKD). Pathalys' initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/18/23 | $150,000,000 |
Abingworth Carlyle Group Catalys Pacific DaVita Venture Group OrbiMed Advisors | undisclosed |
